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ABSTRACT
Objective: The purpose of this study was to evaluate the Amplicor Chlamydia trachomatis Test
(Roche Molecular Systems, Branchburg,NJ), a polymerase chain reaction (PCR)-based technique,
as a screening test for the detection offemale urogenital C. trachomatis infections, comparing it to an
enzyme immunoassay method.
Methods: Endocervical specimens for PCR and Chlamydiazyme (Abbott Laboratories, North
Chicago, IL) analysis were obtained from 328 unselected patients at the outpatient Sexually Trans-
mitted Diseases Clinic at the Allegheny County Health Department, Pittsburgh, PA. In addition,
urethral swabs forPCR analysis were obtained from 256 of these patients.
Results: ByPCR analysis, the prevalence of urogenital chlamydial infections was 15.6% and that
ofcervical chlamydial infections was 10.7%. The sensitivity ofPCR in the detection ofendocervical
chlamydial infections was 89.7% and the specificity was 100%. The positive and negative predictive
values ofPCR were 100% and 99%, respectively. The sensitivity ofChlamydiazyme in the detection
of cervical infections was 61.5% and the specificity was 99.7%, with a positive predictive value of
96.0%. Among all patients with urogenital chlamydial infections, concomitant infections in the
urethra and cervix occurred in 52.5%, whereas the urethra or cervix was solely infected in 35.0%
and 12.5%, respectively.
Conclusions: This PCR-based technique is a rapid screening tool for the diagnosis of urogenital
chlamydial infections and is more sensitive than Chlamydiazyme for endocervical infections in a
sexually transmitted disease clinic population. (C) 1994 Wiley-Liss, Inc.
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hlamydia trachomatis, an obligatory intracellu-
lar bacterium, is one of the most common sex-
ually transmitted organisms in developed countries.
The prevalence of chlamydial infections varies, de-
pending on the population examined, from an esti-
mated 4-5% of all sexually active women in the
United States to as many as 33% of patients attend-
ing sexually transmitted disease (STD) clinics. In
women, C. trachomatis is a major cause of urethri-
tis, cervicitis, and pelvic inflammatory disease.
Long-term sequelae of upper genital tract infec-
tions include infertility, ectopic pregnancy, and
chronic pelvic pain. Recent chlamydial infections
may be associated with premature rupture ofmem-
branes, preterm labor, and late postpartum endo-
myometritis.
2-4 In men, C. trachomatis causes over
40% of cases of non-gonococcal urethritis
5 and is an
important cause of epididymitis, prostatitis, and
proctitis. Vertical transmission of C. trachomatis
can lead to inclusion conjunctivitis in the newborn
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and pneumonia in infants during the first months
of life. In addition to the clinical manifestations
mentioned, there is a high rate of asymptomatic
infection in both males and females; up to 70% of
infected females are asymptomatic.
6
There are a variety of methods available for the
detection of C. trachomatis. While the currently
accepted gold standard diagnostic test is tissue cul-
ture isolation of the organism, its sensitivity is esti-
mated to be only 80%.
7 Moreover, it requires up to
72 h for incubation and is costly. Antigen detection
methods, based on fluorescent monoclonal antibody
(MicroTrak, Syva, Palo Alto, CA) or enzyme-
linked immunoassay (Chlamydiazyme, Abbott Lab-
oratories, North Chicago, IL) methods are widely
used in detecting chlamydial infections. These tests
are less expensive and can be performed more rap-
idly than cell culture; however, they are less sensi-
tive and specific.
8
The polymerase chain reaction (PCR) detects
small quantities of deoxyribonucleic acid (DNA)
by using a DNA polymerase to amplify a target
DNA sequence. The PCR technique has been de-
veloped to detect viral and bacterial infections. PCR
detection of C. trachomatis infections has been eval-
uated in several small studies.
9-11 This technique,
however, is time consuming and labor intensive. A
rapid PCR assay for the detection of C. trachomatis
has been developed recently (Amplicor C. tracho-
matis Test, Roche Molecular Systems, Branchburg,
NJ). The Amplicor test has been demonstrated to
be more sensitive than culture for the detection of
endocervical infections in a high-prevalence obstet-
ric population and more sensitive than Chlamydi-
azyme in a low-prevalence population.
12 This tech-
nique offers both excellent sensitivity and a total
assay time of 4.5 h, which are important character-
istics for a diagnostic or screening tool. In this
study, we evaluated the Amplicor test on lower
genital tract specimens from female patients attend-
ing an STD clinic and compared endocervical spec-
imens with Chlamydiazyme, the primary diagnos-
tic test for C. trachomatis used at our institution.
SUBJECTS AND METHODS
Our study population was comprised of patients
attending the outpatient Sexually Transmitted Dis-
eases Clinic at the Allegheny County Health De-
partment, Pittsburgh, PA. Specimens were ob-
tained from both symptomatic and asymptomatic
women from September 1, 1992, to October 30,
1992. Patients were included in the study if one of
the investigators (H.C.W.) or certain nurse clini-
cians were present to collect the specimens. Cervi-
cal swabs were obtained randomly from 328 unse-
lected female patients attending the clinic, and
urethral swabs were obtained concomitantly from
256 of these patients.
Urethral specimens were obtained by passing a
DacronM-tipped swab into the distal urethra. A
non-lubricated speculum was then placed into the
vagina, excess cervical mucus was removed, and
then endocervical samples were obtained for cul-
ture of Neisseria gonorrhoeae, Chlamydiazyme, and
PCR (Amplicor C. trachomatis Test), in that order.
Cervical swabs for Chlamydiazyme were obtained
prior to those for the Amplicor test in order to
obtain the greatest bacterial inoculum to facilitate
antigen detection. The Chlamydiazyme specimens
were processed as per the manufacturer’s recom-
mendation. The PCR Dacron
TM swabs were placed
in ml of sodium dodecyl sulfate-based specimen
transport media and agitated for 15 sec to displace
the clinical sample into the media. The PCR speci-
mens were sent at room temperature to a single
research laboratory at Magee-Womens Hospital,
Pittsburgh, PA, and these specimens were main-
tained at 4C prior to processing.
PCR amplification was performed on clinical
specimens, negative controls, and positive plasmid
DNA controls according to a procedure described
elsewhere, lz Briefly, 50 I1 of each diluted speci-
men was placed in a PCR reaction tube, to which
was added a 50 I1 aliquot of master mix containing
Taq polymerase, uracil-N-glycosylase, Tris buffer,
KCI, glycerol, deoxynucleotide triphosphates, and
biotinylated oligonucleotide primers specific for the
cryptic plasmid of C. trachomatis. A 2-tempera-
ture, 30-cycle amplification scheme was then con-
ducted in a Perkin Elmer (Norwalk, CT) 9600
thermal cycler.
Sodium hydroxide-based denaturation solution
was added to the amplified specimens whereupon
25 Ixl of each specimen was removed and placed
into a 96-well microtiter detection plate containing
a hybridization buffer. This microtiter plate was
coated with a complementary probe for the ampli-
fied chlamydia cryptic plasmid. The amplified
DNA was then permitted to hybridize, and the
wells were then washed in order to remove unhy-
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TABLE I. Comparison of Chlamydiazyme to PCR
for the detection of endocervical C. trachomatis
Chlamydiazyme PCR results
results Positive Negative Total
Reactive 20 5 25 (7.6%)
Non-reactive 15 288 303
Total 35 (10.7%) 293 328
TABLE 2. Performance of PCR in the detection of
endocervical C. trachomatis (after resolution of
discrepant results)
Resolved specimens
PCR results Positive Negative Total
Positive 35 0 35
Negative 4 289 293
Total 39 289 328
bridized excess amplification reagents. Avidin-
horseradish peroxidase conjugate was added to each
well, followed by a wash to remove unbound conju-
gate. Horseradish peroxidase substrate, containing
hydrogen peroxide and tetramethylbenzidine, was
then added for 10 min. The optical densities were
read at 450 nm in a Biotek ELISA plate reader
(Winooski, VT). Following preestablished crite-
ria,
12 we graded absorbencies >0,25 as positive.
Specimens with initial absorbencies between 0,20
and 0,60 were deemed equivocal and retested, with
the second amplification value used as the final
result.
Discrepant results were analyzed in the follow-
ing manner. Specimens that were positive by PCR
and negative by Chlamydiazyme were reamplified
using primers directed against the major outer
membrane protein (MOMP) gene of C. trachoma-
t/s, as described elsewhere.
12 A negative result after
reamplification indicated contamination by cryptic
plasmid amplicons, whereas a positive result indi-
cated a false negative Chlamydiazyme result. Spec-
imens positive by Chlamydiazyme and negative by
PCR were reamplified after phenol-chloroform,
ethanol-precipitated extraction. A negative result
indicated sampling error, infection with a plasmid-
less strain of C. trachomat#, or a Chlamydiazyme
false positive. A. positive result after extraction sig-
nified the presence, ofPCR inhibitors.
RESULTS
The results of Chlamydiazyme and Amplicor C.
trachomatis Tests on cervical specimens are com-
pared in Table 1. Twenty-five patients (7.6%)
tested positive for C. trachomatis by Chlamydiaz-
yme, and 35 patients (10.7%) were positive by
PCR analysis. Compared to PCR, the sensitivity of
Chlamydiazyme was only 57.1% and the specificity
was 98.3%. The positive predictive value (PPV) of
TABLE 3. Performance of Chlamydiazyme in the
detection of endocervical C. trachomatis (after
resolution of discrepant results)
Chlamydiazyme Resolved specimens
results Positive Negative Total
Positive 24 25
Negative S 288 303
Total 39 289 328
Chlamydiazyme was 80.0% and the negative pre-
dictive value (NPV) was 95.0%.
Discrepant results were noted in 20 specimens.
Fifteen patients were positive by PCR and negative
by Chlamydiazyme. All 15 specimens were con-
firmed as positive after amplification with primers
for the MOMP gene. Four of the 5 specimens
positive by Chlamydiazyme and negative by PCR
were resolved as positive. One specimen remained
negative after phenol-chloroform extraction.
The results of PCR and Chlamydiazyme after
resolution of discrepant results are shown in Tables
2 and 3. The sensitivity ofPCR in detecting endo-
cervical C. trachomatis infections was 89.7% and
the specificity was 100%. The PPV and NPV of
PCR were 100% and 98.6%, respectively. Chlamy-
diazyme demonstrated a sensitivity of 61.5% and a
specificity of 99.7%. The PPV and NPV were
96.0% and 95.0%, respectively. The difference in
sensitivities of PCR and Chlamydiazyme was sig-
nificant (P < 0.01, 2 analysis).
Table 4 displays the results of the Amplicor test
from patients with both urethral and cervical spec-
imens. These paired samples were separately run
using the PCR technique. C. trachomatis was iden-
tified in the cervix in 26 women (10.2%) and ure-
thral chlamydia infections were detected in 35 pa-
tients (13.7%). Forty patients (15.6%) were
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TABLE 4. Comparison of the detection of cervical
and urethral C. trachomatis by PCR
Cervix
Urethra Positive Negative Total
Positive 21 14 35 (I 3.7%)
Negative 5 216 221
Total 26 (10.2%) 230 256
positive for chlamydia in either the cervix or ure-
thra. Twenty-one of 26 patients (80.8%) with cer-
vical chlamydial infections had concomitant ure-
thral chlamydia infections. Likewise, of 35 patients
with positive urethral PCR samples, 21 (60.0%)
were positive for chlamydia in the cervix. Of all
patients with urogenital chlamydial infections, C.
trachomatis was identified in both sites in 21
(52.5%), while 14 (35.0%) were positive only in
the urethra and only 5 (12.5%) were positive solely
in the cervix.
Forty-two women were positive for N. gonor-
rhoeae in the endocervix. Cervical chlamydial in-
fections were detected in 15 (35.7%) of these pa-
tients using PCR, whereas 10 patients (23.8%)
were positive by Chlamydiazyme. Among the 35
patients positive for C. trachomatis by PCR, cervi-
cal coinfection with N. gonorrhoeae occurred in 15
(42.9%).
DISCUSSION
Our study demonstrates the superior sensitivity of
PCR, using the Amplicor C. trachomatis Test, when
compared to enzyme immunoassay (Chlamydiaz-
yme) in the detection of cervical chlamydial infec-
tions in women attending an STD clinic. The sen-
sitivity of PCR in our study was 89.7%, whereas
the sensitivity of Chlamydiazyme was 61.5%
(P < 0.01). In our high-risk population, the PCR
technique detected 15 additional patients who were
negative by enzyme immunoassay. Over 35% of
those patients infected were not identified by
Chlamydiazyme. Chlamydiazyme detected 5 pa-
tients not identified by PCR. Four of these speci-
mens were resolved as positive, whereas remained
negative after discrepant analysis. The 4 false neg-
ative PCR specimens were among the first 15% of
samples analyzed, and we speculate that this may
represent inexperience in the early phases of the
learning curve.
Using PCR, the prevalences of chlamydial cer-
vicitis and urethritis in our population are 10.7%
and 13.7%, respectively, and the prevalence of
urogenital chlamydial infections is 15.6%. Our data
indicate that there is a high rate of concomitant
urethral and cervical chlamydial infections and con-
firm other screening studies in STD clinics that
suggest that 50% ofwomen with urogenital chlamy-
dial infections are infected in both the cervix and
urethra.
13 In our population, C. trachomatis was
detected from both sites in 52.5%, while 35.0%
and 12.5% were infected solely in the urethra and
cervix, respectively. Over one-third of urogenital
chlamydial infections would be missed by failing to
sample the urethra; therefore, this site should be
evaluated when testing for C. trachomatis.
Commonly used laboratory tests to confirm C.
trachomatis infections include tissue culture and an-
tigen detection techniques. While tissue culture us-
ing cycloheximide-treated McCoy cells has long
been considered the gold standard diagnostic test
for C. trachomatis, it will not detect up to 20% of all
chlamydial infections.
7 Its clinical use is limited, as
it is costly, necessitates stringent transport condi-
tions, including refrigeration, and requires at least
48-72 h ofincubation prior to interpretation. Rapid
antigen detection tests have been developed using
either direct immunofluorescence monoclonal anti-
body staining or enzyme-linked immunoassay. The
sensitivities ofthese rapid antigen detection tests are
less than those of culture. Compared to cell culture,
the sensitivities ofdirect immunofluorescence stain-
ing (MicroTrak) and enzyme immunoassay
(Chlamydiazyme) range from 61 to 99% and 60 to
98%, respectively.
14 In addition, the low PPVs of
the antigen detection tests in low-prevalence popu-
lations are concerning. DNA probe assays are addi-
tional diagnostic tests available for C. trachomatis.
The PACE 2 assay (Gen-Probe, Inc., San Diego,
CA) is rapid and convenient, but its sensitivity is
less than cell culture.
15
We chose the Amplicor C. trachomatis Test, a
PCR-based technique, as our gold standard for
chlamydia detection, rather than cell culture. The
efficacy of PCR in the detection of C. trachomatis
infections has been documented.
9-12 In a recent
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study, the Amplicor C. trachomatis Test was dem-
onstrated to have a sensitivity of97% and a specific-
ity of 99.7% in the detection of C. trachomatis in
cervical specimens, whereas the sensitivity of cul-
ture was only 86%.
12 This PCR-based technique is
highly sensitive in the detection of cervical chlamy-
dial infections, superior to culture or enzyme-linked
immunoassays, and may be a better gold standard
for the detection of C. trachomatis infections. We
chose to compare the Amplicor test to Chlamydiaz-
yme, as Chlamydiazyme is the main test used at our
STD clinic and is widely used as the sole diagnostic
test for chlamydial infections. Detecting a greater
proportion of people infected with C. trachomatis
has major public health implications. Rapid testing
may enable earlier treatment which, theoretically,
may prevent the sequelae of chlamydial infections.
Moreover, PCR may be shown, in the future, to be
a better method to test for cure, differentiating
suppression from eradication of the organism. This
may be important in adequately treating pelvic in-
flammatory disease where small inoculum of C.
trachomatis can persist, causing ongoing tubal dam-
age, perhaps through the immune response to
chlamydial heat-shock proteins.
16
Unlike cell culture, clinical specimens for Am-
plicor C. trachomatis Test analysis can be trans-
ported at room temperature, and chlamydial DNA
is stable for 6 months when refrigerated in trans-
port medium.
12 The Amplicor system assay is
rapid; laboratory processing is only 4.5 h, which
compares favorably to the assay times of the antigen
detection methods. When chlamydial organisms are
present in small amounts, the rapid antigen detec-
tion tests are less likely to detect the low levels of
antigen present. The PCR method enables the de-
tection of small quantities of specific DNA frag-
ments and has the potential to identify DNA from
organisms present in low concentrations. The mate-
rial and labor costs of this kit depend on the volume
of assays performed. In most centers, the total cost
will be approximately $20, somewhat more than
the cost of Chlamydiazyme but much less than that
of cell culture.
Our study demonstrates that the Amplicor C.
trachomatis Test, a PCR-based process for the de-
tection of C. trachomatis, is a rapid and simple
diagnostic test for the detection offemale urogenital
chlamydial infections and is superior to Chlamydi-
azyme in detecting endocervical infections in an
STD clinic population.
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